Comparative Pharmacology
Head-to-head clinical analysis: IONTOCAINE versus XYLOCAINE VISCOUS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IONTOCAINE versus XYLOCAINE VISCOUS.
IONTOCAINE vs XYLOCAINE VISCOUS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iontocaine (lidocaine 2% and epinephrine 0.01%) combines a sodium channel blocker (lidocaine) to inhibit nerve impulse propagation, producing local anesthesia, with epinephrine causing vasoconstriction to reduce systemic absorption and prolong effect.
Lidocaine is an amide-type local anesthetic that blocks voltage-gated sodium channels, inhibiting nerve impulse propagation and reducing pain sensation.
IONTOCAINE is not a recognized drug. No standard dosing available.
Adults: 5-15 mL orally (or swish and spit) 4-6 times daily, not to exceed 4 doses in 12 hours or 30 mL in 12 hours.
None Documented
None Documented
Terminal elimination half-life is 2.5-3.0 hours; prolonged in renal impairment (up to 6-8 hours).
Terminal elimination half-life: 1.5-2 hours in adults; prolonged in hepatic impairment or heart failure (up to 6-8 hours). In neonates, half-life may be 3-6 hours due to immature metabolism.
Primarily renal excretion of unchanged drug (70-80%) and glucuronide conjugate (15-20%); less than 10% fecal.
Renal excretion of metabolites: ~90%. Unchanged drug: <10%. Biliary/fecal: minor.
Category C
Category C
Local Anesthetic
Local Anesthetic